Megan E McCarthy1, Catalin S Buhimschi2, John T Hardy1, Antonette T Dulay1, Christine A Laky1, Mert-Ozan Bahtyiar1, Ramesha Papanna1, Guomao Zhao3, Irina A Buhimschi4. 1. Department of Ob/Gyn & Reproductive Sciences, Yale University School of Medicine, New Haven, CT, 0675, USA. 2. Department of Obstetrics & Gynecology, The Ohio State University College of Medicine, Columbus, OH, 43210, USA. 3. Center for Perinatal Research, The Research Institute at Nationwide Children's Hospital, Columbus, OH, 43215, USA. 4. Center for Perinatal Research, The Research Institute at Nationwide Children's Hospital, Columbus, OH, 43215, USA. Electronic address: irina.buhimschi@nationwidechildrens.org.
Abstract
OBJECTIVE: Haptoglobin (Hp) has key immunoregulatory roles that vary with phenotype (Hp1-1, Hp2-1, Hp2-2). Cord blood Hp expression is switched-off in the normal fetus. We hypothesized that in the setting of fetal inflammation placenta becomes inundated with Hp of fetal origin that in turn modulates the output of PGE2 and MMP-9 in a phenotype dependent manner. METHODS: Placentas from 40 pregnancies complicated by preterm birth (PTB) (<37 weeks), without (n = 15) or with (n = 25) intra-amniotic infection and histological chorioamnionitis (HCA) were scored for intensity of Hp immunostaining. Hp mRNA levels were evaluated by PCR. Cord blood Hp levels, switch-on status and phenotypes were determined by ELISA and Western blotting. Using a villous trophoblast explant system we investigated if Hp can modulate the release of PGE2 and MMP-9 in the presence or absence of lipopolysaccharide (LPS). RESULTS: All cases with HCA had positive Hp immunoreactivity within fetal vascular spaces. Hp staining intensity correlated with cord blood Hp levels and IL-6. Placentas with and without HCA had similar Hp mRNA levels suggesting Hp immunostaining in the fetal spaces is of fetal rather than placental origin. Both Hp1-1 and Hp2-2 up-regulated PGE2 release in the presence of LPS (2-fold over the LPS level, P < .05), without affecting MMP-9 concentrations. CONCLUSIONS: Fetal Hp switch-on status, a marker of antenatal exposure to intra-amniotic infection/inflammation, can be reliably established through evaluation of archived placental specimens. In the setting of infection/inflammation, Hp enhances placental PGE2 output thereby supporting the role of the fetus in triggering parturition.
OBJECTIVE:Haptoglobin (Hp) has key immunoregulatory roles that vary with phenotype (Hp1-1, Hp2-1, Hp2-2). Cord blood Hp expression is switched-off in the normal fetus. We hypothesized that in the setting of fetal inflammation placenta becomes inundated with Hp of fetal origin that in turn modulates the output of PGE2 and MMP-9 in a phenotype dependent manner. METHODS: Placentas from 40 pregnancies complicated by preterm birth (PTB) (<37 weeks), without (n = 15) or with (n = 25) intra-amniotic infection and histological chorioamnionitis (HCA) were scored for intensity of Hp immunostaining. Hp mRNA levels were evaluated by PCR. Cord blood Hp levels, switch-on status and phenotypes were determined by ELISA and Western blotting. Using a villous trophoblast explant system we investigated if Hp can modulate the release of PGE2 and MMP-9 in the presence or absence of lipopolysaccharide (LPS). RESULTS: All cases with HCA had positive Hp immunoreactivity within fetal vascular spaces. Hp staining intensity correlated with cord blood Hp levels and IL-6. Placentas with and without HCA had similar Hp mRNA levels suggesting Hp immunostaining in the fetal spaces is of fetal rather than placental origin. Both Hp1-1 and Hp2-2 up-regulated PGE2 release in the presence of LPS (2-fold over the LPS level, P < .05), without affecting MMP-9 concentrations. CONCLUSIONS: Fetal Hp switch-on status, a marker of antenatal exposure to intra-amniotic infection/inflammation, can be reliably established through evaluation of archived placental specimens. In the setting of infection/inflammation, Hp enhances placental PGE2 output thereby supporting the role of the fetus in triggering parturition.
Authors: Rosemary D Higgins; George Saade; Richard A Polin; William A Grobman; Irina A Buhimschi; Kristi Watterberg; Robert M Silver; Tonse N K Raju Journal: Obstet Gynecol Date: 2016-03 Impact factor: 7.661
Authors: Lissa K Magloire; Catalin S Buhimschi; Christian M Pettker; Anna K Sfakianaki; Benjamin D Hamar; Vineet Bhandari; Irina A Buhimschi Journal: Am J Obstet Gynecol Date: 2006-07-26 Impact factor: 8.661
Authors: Mahmoud Suleiman; Doron Aronson; Rabea Asleh; Michael R Kapeliovich; Ariel Roguin; Simcha R Meisel; Michael Shochat; Abeer Sulieman; Shimon A Reisner; Walter Markiewicz; Haim Hammerman; Rachel Lotan; Nina S Levy; Andrew P Levy Journal: Diabetes Date: 2005-09 Impact factor: 9.461
Authors: Karen L Archabald; Irina A Buhimschi; Mert O Bahtiyar; Antonette T Dulay; Sonya S Abdel-Razeq; Christian M Pettker; Heather S Lipkind; John T Hardy; Megan E McCarthy; Guomao Zhao; Vineet Bhandari; Catalin S Buhimschi Journal: Fetal Diagn Ther Date: 2016-10-29 Impact factor: 2.208
Authors: Christy J Hanthorn; Grant A Dewell; Renee D Dewell; Vickie L Cooper; Chong Wang; Paul J Plummer; Jeffrey Lakritz Journal: BMC Vet Res Date: 2014-12-06 Impact factor: 2.741
Authors: Leeann R Pavlek; Sundari Vudatala; Christopher W Bartlett; Irina A Buhimschi; Catalin S Buhimschi; Lynette K Rogers Journal: Pediatr Res Date: 2020-05-09 Impact factor: 3.756